MET
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
MetLife, Inc.
- Nom
- MetLife, Inc.
- Secteur
- Financial Services
- Industrie
- Insurance - Life
- Bourse
- NYSE
- Capitalisation
- $62.8B
- Employés
- 46,000
- PDG
- Michel Abbas Khalaf
- Site web
- https://www.metlife.com
- Marché
- AFLBHFCNOGLLNCMFC
MetLife, Inc. operates as a leading global financial services entity, delivering an extensive array of services encompassing insurance, annuities, employee benefits, and asset management. The company manages its operations through five primary divisions: the U.S., Asia, Latin America, Europe, the Middle East and Africa (EMEA), and MetLife Holdings. Its broad insurance offerings include life, dental, group short-term and long-term disability, individual disability, pet, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans. MetLife also supports employers with administrative services-only (ASO) arrangements. Furthermore, it provides sophisticated financial instruments such as general and separate account contracts, synthetic guaranteed interest contracts, and private floating rate funding agreements. The company facilitates pension risk transfers, offers institutional income annuities, structures settlements, and delivers capital markets investment products. Specialized life insurance products and funding agreements are also available for post-retirement benefits, alongside company, bank, or trust-owned life insurance used to finance non-qualified executive benefit programs. In addition, MetLife offers a variety of annuity options including fixed, indexed-linked, and variable, alongside pension and regular savings products. Its life insurance portfolio features whole life, term life, endowments, universal and variable life, and group life policies. The company also provides longevity reinsurance solutions, credit insurance products, and protection for long-term healthcare services. MetLife, Inc. was founded in 1863 and is headquartered in New York City.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-10-06 10:56:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-06-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-26 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-08-06 | Gilbert Ray Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-07-11 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-06-13 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-25 | Zoe Lofgren | Sale (Full) | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-04-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-03-24 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-03 | Kathy E. Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-07-20 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2022-07-19 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2022-06-17 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-16 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2022-05-05 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-03-16 | John Henry Rutherford | Sale (Full) | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-06-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-06-02 | Ro Khanna | Sale (Partial) | $1,001 - $15,000 |
| 2021-06-01 | Ro Khanna | Sale (Partial) | $1,001 - $15,000 |
| 2021-04-16 | Marie Newman | Sale (Full) | $1,001 - $15,000 |
| 2021-04-05 | Marie Newman | Purchase | $1,001 - $15,000 |
| 2021-03-05 | Ro Khanna | Sale (Partial) | $1,001 - $15,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2020-11-20 | Joseph Morelle | Sale (Full) | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-02-25 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-01-07 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2019-07-15 | Bill Flores | Purchase | $15,001 - $50,000 |
| 2019-02-13 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2019-01-23 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2019-01-04 | Dean Phillips | Sale (Partial) | $15,001 - $50,000 |
| 2018-12-06 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2018-07-25 | Thomas Suozzi | Sale (Full) | $1,001 - $15,000 |
| 2018-07-12 | Gary James Palmer | Purchase | $1,001 - $15,000 |
| 2017-08-17 | Thomas Suozzi | Purchase | $1,001 - $15,000 |
| 2017-07-17 | John Henry Rutherford | Purchase | $1,001 - $15,000 |
| 2017-07-03 | David Joyce | Sale (Full) | $15,001 - $50,000 |
Signal
Neutral signalScored 2026-10-06 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
MET presents a meaningful earnings catalyst with Group Benefits up 25% and favorable sector tailwinds from high Treasury yields and record annuity sales, but these positive signals are severely undermined by deeply…
The first sentence of the analysis written for MET on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 0.65 · operating margin 6.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 36.4% | 27.2% | 25.5% | 27.9% | 26.6% | |
| Ebit Margin | 7.4% | 9.5% | 4.7% | 10.7% | 14.9% | |
| Ebitda Margin | 8.4% | 10.5% | 5.8% | 11.7% | 16.0% | |
| Operating Profit Margin | 6.0% | 8.0% | 3.2% | 9.4% | 13.4% | |
| Pretax Profit Margin | 6.0% | 8.0% | 3.2% | 9.4% | 13.4% | |
| Continuous Operations Profit Margin | 4.4% | 6.4% | 2.4% | 7.8% | 10.9% | |
| Net Profit Margin | 4.4% | 6.3% | 2.3% | 7.8% | 10.8% | |
| Bottom Line Profit Margin | 4.1% | 6.0% | 2.0% | 7.5% | 10.5% | |
| Current Ratio | 0.650 | 0.554 | 1.361 | 1.336 | 1.474 | |
| Quick Ratio | 0.650 | 0.554 | 1.361 | 1.336 | 1.474 | |
| Solvency Ratio | 0.006 | 0.008 | 0.003 | 0.009 | 0.011 | |
| Cash Ratio | 0.080 | 0.078 | 0.080 | 0.080 | 0.076 | |
| Price To Earnings Ratio | 16.446 | 13.692 | 36.335 | 11.397 | 8.116 | |
| Price To Earnings Growth Ratio | -0.833 | 0.060 | -0.509 | -0.650 | 0.234 | |
| Forward Price To Earnings Growth Ratio | -0.833 | 0.060 | -0.509 | -0.650 | 0.234 | |
| Price To Earnings Diluted Ratio | 16.446 | 13.785 | 36.536 | 11.487 | 8.169 | |
| Price To Earnings Diluted Growth Ratio | -0.857 | 0.060 | -0.513 | -0.651 | 0.236 | |
| Price To Book Ratio | 1.848 | 2.056 | 1.680 | 1.887 | 0.764 | |
| Price To Sales Ratio | 0.681 | 0.807 | 0.745 | 0.830 | 0.814 | |
| Price To Free Cash Flow Ratio | 2.899 | 3.733 | 3.536 | 4.958 | 4.022 | |
| Price To Operating Cash Flow Ratio | 2.899 | 3.733 | 3.536 | 4.958 | 4.022 | |
| Debt To Assets Ratio | 0.027 | 0.028 | 0.027 | 0.027 | 0.023 | |
| Debt To Equity Ratio | 0.711 | 0.682 | 0.627 | 0.602 | 0.258 | |
| Debt To Capital Ratio | 0.415 | 0.405 | 0.385 | 0.376 | 0.205 | |
| Long Term Debt To Capital Ratio | 0.396 | 0.399 | 0.384 | 0.373 | 0.202 | |
| Financial Leverage Ratio | 26.240 | 24.684 | 22.908 | 22.190 | 11.258 | |
| Working Capital Turnover Ratio | -0.729 | -6.362 | 0.763 | 0.650 | 1.015 | |
| Operating Cash Flow Ratio | 0.066 | 0.059 | 0.055 | 0.045 | 0.049 | |
| Operating Cash Flow Sales Ratio | 0.235 | 0.216 | 0.211 | 0.167 | 0.202 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | 1.990 | 4.125 | 2.891 | 6.211 | 6.733 | |
| Interest Coverage Ratio | 4.393 | 5.421 | 2.069 | 6.785 | 9.259 | |
| Short Term Operating Cash Flow Coverage Ratio | 11.598 | 32.508 | 119.832 | 64.989 | 37.616 | |
| Operating Cash Flow Coverage Ratio | 0.897 | 0.808 | 0.757 | 0.633 | 0.736 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 10.631 | 8.753 | 8.084 | 6.379 | 6.964 | |
| Dividend Payout Ratio | 0.504 | 0.390 | 1.118 | 0.337 | 0.269 | |
| Enterprise Value Multiple | 7.821 | 7.470 | 12.384 | 6.792 | 4.833 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 36.4% | ▲9.2% | ▲7.7% |
| Ebit Margin | 7.4% | ▼-2.1% | ▼-2.0% |
| Ebitda Margin | 8.4% | ▼-2.1% | ▼-2.1% |
| Operating Profit Margin | 6.0% | ▼-2.0% | ▼-2.0% |
| Pretax Profit Margin | 6.0% | ▼-2.0% | ▼-2.0% |
| Continuous Operations Profit Margin | 4.4% | ▼-1.9% | ▼-1.9% |
| Net Profit Margin | 4.4% | ▼-1.9% | ▼-1.9% |
| Bottom Line Profit Margin | 4.1% | ▼-1.9% | ▼-1.9% |
| Current Ratio | 0.650 | ▲0.096 | ▼-0.425 |
| Quick Ratio | 0.650 | ▲0.096 | ▼-0.425 |
| Solvency Ratio | 0.006 | ▼-0.002 | ▼-0.002 |
| Cash Ratio | 0.080 | ▲0.002 | ▲0.001 |
| Price To Earnings Ratio | 16.446 | ▲2.753 | ▼-0.751 |
| Price To Earnings Growth Ratio | -0.833 | ▼-0.893 | ▼-0.494 |
| Forward Price To Earnings Growth Ratio | -0.833 | ▼-0.893 | ▼-0.494 |
| Price To Earnings Diluted Ratio | 16.446 | ▲2.661 | ▼-0.839 |
| Price To Earnings Diluted Growth Ratio | -0.857 | ▼-0.917 | ▼-0.512 |
| Price To Book Ratio | 1.848 | ▼-0.208 | ▲0.201 |
| Price To Sales Ratio | 0.681 | ▼-0.126 | ▼-0.094 |
| Price To Free Cash Flow Ratio | 2.899 | ▼-0.834 | ▼-0.930 |
| Price To Operating Cash Flow Ratio | 2.899 | ▼-0.834 | ▼-0.930 |
| Debt To Assets Ratio | 0.027 | ▼-0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.711 | ▲0.029 | ▲0.135 |
| Debt To Capital Ratio | 0.415 | ▲0.010 | ▲0.058 |
| Long Term Debt To Capital Ratio | 0.396 | ▼-0.003 | ▲0.045 |
| Financial Leverage Ratio | 26.240 | ▲1.556 | ▲4.784 |
| Working Capital Turnover Ratio | -0.729 | ▲5.633 | ▲0.204 |
| Operating Cash Flow Ratio | 0.066 | ▲0.007 | ▲0.011 |
| Operating Cash Flow Sales Ratio | 0.235 | ▲0.019 | ▲0.029 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 |
| Debt Service Coverage Ratio | 1.990 | ▼-2.135 | ▼-2.400 |
| Interest Coverage Ratio | 4.393 | ▼-1.028 | ▼-1.192 |
| Short Term Operating Cash Flow Coverage Ratio | 11.598 | ▼-20.909 | ▼-41.710 |
| Operating Cash Flow Coverage Ratio | 0.897 | ▲0.089 | ▲0.131 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Dividend Paid And Capex Coverage Ratio | 10.631 | ▲1.879 | ▲2.469 |
| Dividend Payout Ratio | 0.504 | ▲0.114 | ▼-0.020 |
| Enterprise Value Multiple | 7.821 | ▲0.351 | ▼-0.039 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $52.49B | $56.43B | $50.42B | $56.38B | $51.59B | |
| Enterprise value | $50.64B | $55.08B | $48.61B | $54.17B | $48.97B | |
| EV / Sales | 0.66x | 0.79x | 0.72x | 0.80x | 0.77x | |
| EV / Op. cash flow | 2.80x | 3.64x | 3.41x | 4.76x | 3.82x | |
| EV / Free cash flow | 2.80x | 3.64x | 3.41x | 4.76x | 3.82x | |
| EV / EBITDA | 7.82x | 7.47x | 12.38x | 6.79x | 4.83x | |
| Net debt / EBITDA | -0.29x | -0.18x | -0.46x | -0.28x | -0.26x | |
| Current ratio | 0.65x | 0.55x | 1.36x | 1.34x | 1.47x | |
| Income quality | 5.36x | 3.42x | 9.04x | 2.15x | 1.96x | |
| Graham number | $70 | $76 | $43 | $77 | $124 | |
| Graham net-net | -$827 | -$748 | -$413 | -$389 | -$374 | |
| Tax burden | 72.5% | 78.7% | 73.0% | 83.0% | 80.5% | |
| Interest burden | 81.5% | 84.4% | 67.4% | 87.2% | 90.3% | |
| Working capital | -$96.55B | -$115.03B | $93.04B | $84.41B | $124.84B | |
| Invested capital | -$64.13B | -$84.65B | $124.42B | $115.28B | $150.43B | |
| Return on assets | 0.5% | 0.7% | 0.2% | 0.8% | 0.9% | |
| Operating ROA | 0.7% | 0.8% | 0.3% | 0.9% | 1.1% | |
| Return on tangible assets | 0.5% | 0.7% | 0.2% | 0.8% | 0.9% | |
| Return on equity | 11.9% | 16.1% | 5.3% | 17.7% | 10.2% | |
| Return on invested capital | 0.7% | 1.1% | 0.4% | 1.3% | 1.4% | |
| Return on capital employed | 1.0% | 1.3% | 0.5% | 1.5% | 1.7% | |
| Earnings yield | 6.4% | 7.8% | 3.1% | 9.4% | 13.3% | |
| Free cash flow yield | 34.5% | 26.8% | 28.3% | 20.2% | 24.9% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 8.6% | 9.1% | 8.6% | 9.1% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 4.1% | 4.2% | 4.3% | 4.4% | 3.4% | |
| Days sales outstanding | 257d | 179d | 182d | 119d | 118d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 257d | 179d | 182d | 119d | 118d | |
| Cash conversion cycle | 257d | 179d | 182d | 119d | 118d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-05 Argent Capital Management LLC Buys 121,303 Shares of MetLife, Inc. $MET Argent Capital Management LLC purchased a new stake in MetLife, Inc. (NYSE: MET) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 121,303 shares of the financial services provider''s stock, valued at approximately $11,422,000. Several other hedge funds have also modified their
- 2026-09-22 Can MetLife''s Group Benefits Segment Maintain Its Momentum? MET''s Group Benefits earnings jump 25% in Q2 2026, fueled by stronger underwriting and demand, but some mortality gains may fade.
- 2026-09-19 The 30-Year Treasury Yield Just Hit a 19-Year High. Life Insurers Reinvest at Those Rates for Decades. Life insurers generally benefit from higher rates, but there are some negatives to consider.
- 2026-09-17 3 Life Insurers to Watch as Annuity Sales Hit First-Half Record Highs Record annuity demand creates opportunities for Prudential, Principal Financial and MetLife as retirement needs and pension solutions grow.
- 2026-09-16 MetLife Investment Management Closes Galaxy 38 CLO MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the close of Galaxy 38 CLO, Ltd.
- 2026-09-16 MetLife Investment Management Closes Galaxy 38 CLO WHIPPANY, N.J.--(BUSINESS WIRE)--MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE: MET), today announced the close of Galaxy 38 CLO, Ltd. (Galaxy 38), a $450 million target par new issue collateralized loan obligation (CLO). PineBridge Investments, which is part of MIM, serves as collateral manager for the transaction. BofA Securities, Inc. acted as arranger. Galaxy 38 marks the 45th CLO issuance by the Leveraged Finance team, building on t.
- 2026-09-15 RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
- 2026-09-14 Global Indemnity Group (NASDAQ:GBLI) & MetLife (NYSE:MET) Head-To-Head Analysis MetLife (NYSE: MET - Get Free Report) and Global Indemnity Group (NASDAQ: GBLI - Get Free Report) are both finance companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk. Valuation and Earnings This table compares MetLife and
- 2026-09-14 NewEdge Advisors LLC Boosts Holdings in MetLife, Inc. $MET NewEdge Advisors LLC boosted its stake in shares of MetLife, Inc. (NYSE: MET) by 20.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 74,002 shares of the financial services provider''s stock after purchasing an additional 12,378 shares during
- 2026-09-13 Johnson & Johnson''s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson and Johnson''s RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi